← Markets

Geron Corporation

GERN · NASDAQ

Market closed$1.44$0.020000 (+1.41%)After hours $1.42 · -1.39%

Key statistics

Previous close$1.42
Open$1.41
Day high$1.49
Day low$1.40
52-week high$2.01
52-week low$1.04
Market cap923.79M
Volume4.78M
Average volume13.52M
P/E ratio-16.00
Forward P/E—
EPS-0.09
Dividend yield0.00%

Market context

Why it moved

Geron Corporation's stock edged higher today, supported by modest buying interest and positive market sentiment around the biopharmaceutical sector, as the stock continued to recover within its recent trading range.

Yahoo FinanceStockinvestFacebookEmpathiInstagram

What is happening

Recent company-specific developments and publisher coverage.

July 18, 2026Geron Corporation edged higher, closing up about 1.4%, as investors digested the recent appointment of a new Chief Business Officer, Chinmaya Rath, who received a 1.7 million share option grant at $1.42 — signaling leadership investment in the company's commercial trajectory for RYTELO. The move comes as Geron works toward its 2026 revenue guidance of $220–$240 million for the blood cancer therapy, while broader biotech sentiment received a boost from UBS upgrading the healthcare sector as a key allocation amid improving fundamentals and an M&A-friendly environment.

1.4085

July 15, 2026Geron Corporation closed modestly lower as investors digested the appointment of Chinmaya Rath as Chief Business Officer, a veteran dealmaker from Novartis and Cellworks tapped to maximize the value of blood cancer therapy RYTELO globally and support the company's hematology ambitions. The leadership addition comes on the heels of a strong Q1 2026 beat—$61.8M in revenue (+31% YoY) and a narrower-than-expected EPS loss of -$0.01—and builds on Geron's 2026 RYTELO revenue guidance of $220–$240M, though analysts maintain a cautious-to-bullish range with consensus price targets around $5.00 versus the current sub-$1.50 stock price.

-2.8169

July 14, 2026Geron Corporation shares fell nearly 5.5% as broader market weakness — driven by renewed U.S.-Iran military tensions and a sharp oil price surge — weighed on equities broadly. Despite the pullback, the company made a notable leadership move, appointing Chinmaya Rath, a veteran dealmaker from Novartis and Cellworks, as Chief Business Officer to help maximize RYTELO's global commercial potential. The hire signals ambition as Geron tracks toward its full-year RYTELO revenue guidance of $220–$240M, following a strong Q1 where revenue hit $61.8M — a 31% year-over-year increase — and EPS of -$0.01 beat estimates.

-5.3333

July 10, 2026Geron Corporation closed little changed on the session but has surged roughly 23% in July amid a powerful biotech sector rally, ranking among the top monthly gainers on NASDAQ. The backdrop is highly supportive: CNBC's Jim Cramer called biotech 'the hottest group in the market,' citing a more favorable FDA regulatory environment and a wave of M&A activity—Gilead's $7.8B Arcellx deal and Eli Lilly's string of acquisitions signal that well-positioned small-cap biotechs could become takeover targets. Health care has been the leading S&P 500 sector for two consecutive weeks, and Geron, with its approved telomerase inhibitor imetelstat (Rytelo) for myelodysplastic syndromes, fits the profile of a company investors are re-evaluating for acquisition potential.
July 9, 2026Geron Corporation rallied nearly 5% on Wednesday, outperforming broader markets that came under pressure from escalating U.S.-Iran tensions and surging oil prices. The biotech sector continued to act as a relative safe haven, with healthcare leading the S&P 500 for a second consecutive week. Sentiment around Geron remains anchored to the commercial trajectory of RYTELO (imetelstat), its FDA-approved treatment for lower-risk MDS, with analysts maintaining a $5.00 price target and the company guiding for $220–$240M in 2026 revenues. Jim Cramer recently called biotech "the hottest group in the market," citing a more favorable FDA environment and an anticipated wave of M&A—a backdrop that could benefit smaller names like Geron.

4.698

July 8, 2026Geron Corporation shares rose amid a broader surge in biotech sentiment, with CNBC's Jim Cramer calling biotech 'the hottest group in the market' and predicting an M&A flood driven by a more favorable FDA regulatory environment. The healthcare sector continues to outperform, with XLV near its 52-week high after back-to-back weeks as the top S&P 500 sector. For Geron specifically, analysts maintain a $5.00 price target with expectations for 62%+ annual earnings growth, as the company executes on its RYTELO commercial ramp — targeting $220–$240M in 2026 revenue — while pursuing European expansion and advancing its IMpactMF Phase 3 trial in myelofibrosis.

3.4722

July 7, 2026Geron Corporation surged nearly 6% as the healthcare sector outperformed and broader market sentiment improved, with the S&P 500 advancing on a semiconductor rebound and easing oil prices. Investor focus remains on the commercial ramp of RYTELO, Geron's blood cancer therapy for lower-risk myelodysplastic syndromes (LR-MDS), which generated $183.6 million in full-year 2025 revenue, with 2026 guidance of $220–$240 million. The company is also awaiting initial data from real-world studies in the second half of 2026 that could expand RYTELO's addressable market.

5.8824

July 3, 2026Geron Corporation surged over 7% as the healthcare sector outperformed the broader market, with XLV closing near its 52-week high amid a broad-based healthcare rally driven by softer-than-expected U.S. June jobs data that dampened rate-hike expectations. Investor focus remains on Geron's commercial trajectory for Rytelo, with a recent Seeking Alpha analysis highlighting that incoming CEO Harout Semerjian — nearing his one-year mark — could be a catalyst for revitalization after the drug's early launch setbacks, with the IMpactMF trial readout potentially serving as a key upcoming inflection point.

7.0866

Stock Titan · July 14, 2026Geron's New Business Chief Gets Option on 1.7M SharesGlobeNewswire · July 14, 2026Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Stock Titan · July 13, 2026Veteran dealmaker from Novartis and Cellworks joins Geron to steer RYTELO growthInvesting.com · July 13, 2026Geron appoints Chinmaya Rath as chief business officerSeeking Alpha · July 1, 2026Geron Corporation: Commercial Performance Could Dovetail With IMpactMF Run-Up (GERN)StocksToTrade · June 22, 2026GERN Stock Steadies As Geron Builds Commercial MomentumStock Titan · June 1, 2026Geron plans Goldman Sachs healthcare fireside chat, webcast June 8Stock Titan · April 14, 2026New Geron legal chief gets option to buy 2.5M shares at $1.73
Benzinga · May 12, 2026Geron To Present Real-World Moffitt Cancer Center Study Showing RYTELO (imetelstat) Safety And Efficacy In Lower-Risk MDS At EHA 2026
Mt Newswire · May 6, 2026Geron Shares Fall After Reporting Q1 Results
Benzinga · May 6, 2026Geron Reports Q1 2026 Results: Full Earnings Call Transcript
Mt Newswire · May 6, 2026Earnings Flash (GERN) Geron Posts Q1 Net Loss $0.01 a Share, vs. FactSet Est of $0.02 Loss
Mt Newswire · May 6, 2026Earnings Flash (GERN) Geron Corporation Reports Q1 Revenue $51.8M
Benzinga · May 6, 2026Geron Q1 EPS $(0.01) Beats $(0.02) Estimate, Sales $51.771M Beat $50.582M Estimate
Benzinga · March 2, 2026Geron Files Prospectus For Offering Mixed Shelf; Terms Not Disclosed
Mt Newswire · February 25, 2026Geron Q4 Loss Widens, Revenue Rises

Peers

S&P 500SPX · $7,457.69-1.01%Alkermes plcALKS · $52.72+1.50%Celldex Therapeutics, Inc.CLDX · $35.35-0.14%BioCryst Pharmaceuticals, Inc.BCRX · $9.29+2.03%Zenas BioPharma, Inc.ZBIO · $29.53+4.57%Incyte CorporationINCY · $117.25+0.51%Bristol-Myers Squibb CompanyBMY · $60.74+0.38%Fate Therapeutics, Inc.FATE · $2.78+1.83%Verastem, Inc.VSTM · $6.03+4.51%Kura Oncology, Inc.KURA · $10.86-0.28%Rigel Pharmaceuticals, Inc.RIGL · $40.54-2.71%